Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cistron Biotechnology(CIST)$.30 -- Ignore unavailable to you. Want to Upgrade?

To: Tom Bourbulas who wrote (2495)	10/3/1999 11:00:00 PM
From: Walter Morton	Read Replies (1) \| Respond to of 2742

It seems that they are making some tough decisions to make the company profitable. But lets consider that CIST is going to sell the company in parts. What value would you apply to: The $31 million deal with PMC? The new ICE product? The IL-1X patents? PAI-2 patent that is in Phase II clinical trials ("The current estimate is that the results of the trials will come about July, 2000.")? "Cistron granted a sublicense to the PAI-2 DNA Patents to Biotech to make, use and sell PAI-2 protein for therapeutic products in the U.S. Cistron has been advised by Biotech that it opened an Australian manufacturing facility in October 1994, concluded a preliminary safety study using PAI-2 to treat leg ulcers, initiated a 20 patient clinical trial on patients with leg ulcers, which was co-funded by the Australian government, and is currently in a 130-140 patient Phase II trial." Remember this email from Biotech Australia: Message 11204892 I would not be surprised if R&D Systems of Techne (TECH) merged with CIST. Also, don't forget that Biotech Australia is looking for a partner.

To: Tom Bourbulas who wrote (2495)	10/8/1999 12:15:00 AM
From: Walter Morton	Respond to of 2742

From Skin & Allergy News Topical PAI-2 Seems to Improve Healing of Venous Ulcers David R. Branch, Contributing Writer [Skin & Allergy News 30(3):36, 1999. ¸ 1999 International Medical News Group.] Orlando, Fla. -- Suppression of plasminogen activators in chronic venous leg ulcers appears to improve healing of these wounds and may open up opportunities for effective topical therapy. This was the finding of an Australian pilot study reported at a meeting on wound healing sponsored by International Business Communications. Plasminogen activator inhibitor 2 (PAI-2) suppresses the activity of urinary plasminogen activator (uPA) and, to a lesser extent, tissue plasminogen activator (tPA) in wound fluid. Topical application of PAI-2 was associated with healing of venous ulcers in a double-blind, placebo-controlled trial of 20 patients, C. L. Bunn, Ph.D., said in a poster presentation at the meeting. The median ulcer area in 11 patients who received the active drug was reduced by 24% over 29 days, compared with a slight increase in median ulcer area among nine placebo patients, said Dr. Bunn of Biotech Australia, Roseville, New South Wales. In the trial, PAI-2 or the placebo was applied to the ulcers once daily for 5 consecutive days. All patients received standard four-layer compression bandaging. Wound area was determined by tracing at days 1, 5, 15, 22, and 29. Levels of uPA activity -- which has been associated in previous studies with increased proteolysis in wound beds -- were measured at 2 hours after treatment, 4 hours, 6 hours, and on days 2, 3, 4, 5, and 29. There was a significant decrease in uPA activity during the first 6 hours after administration of PAI-2, but it returned to pretreatment levels after 24 hours, despite continued daily application of the topical agent, Dr. Bunn noted. There were no adverse events related to trial medication. The clinical trial was carried out at Fremantle Hospital, Western Australia, under the direction of Dr. Michael C. Stacey of the department of surgery. Based on the results of this small pilot study, a larger clinical trial is now underway. It was originally believed that PAI-2 occurred mainly in the placenta and in the monocyte/macrophage cell lineage, but recent studies have shown that it appears in significant amounts in skin, gingival crevicular fluid, fibroblasts, mesothelial cells, and vascular smooth muscle. It appears to protect against excessive proteolysis, especially in the presence of inflammation; stabilize the extracellular matrix and stratum corneum; and prevent apoptosis, Dr. Bunn said. Comparison of biologic activity in wound fluids in patients with venous leg ulceration and in those with acute wounds suggests that the former represents a persistent inflammatory state.

To: Tom Bourbulas who wrote (2495)	11/5/1999 2:26:00 PM
From: Walter Morton	Respond to of 2742

How much more time does CIST need before they tell us whether or not a deal has been struck?

To: Tom Bourbulas who wrote (2495)	11/15/1999 3:58:00 PM
From: Walter Morton	Respond to of 2742

10Q Filed 11/15/99 - Interest Income was lower as compared to 1998. - No Income tax (benefit) as compared to 1998. - Equity has reduced by $1.4 million since June 1999. Unaudited.